Peter Foley

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

Medicine, Dermatology, Immunology +17

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Kristian Reich, April W. Armstrong, Peter Foley et al. · Journal of the American Academy of Dermatology · 2017 · 731 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon, Bruce Strober, Mark Lebwohl et al. · The Lancet · 2018 · 662 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

Kim Papp, Kenneth B. Gordon, Diamant Thaçi et al. · New England Journal of Medicine · 2018 · 414 citations · Full text

Life Sciences, Dermatology, Pharmacology +17

Incidence of non-melanocytic skin cancer treated in Australia

Graham G. Giles, Robin Marks, Peter Foley · BMJ · 1988 · 360 citations · Full text

Medicine, Dermatology, Oncology +15